Blog Elements
You can display blog posts in various ways with the “Blog Post” element/shortcode. You can see one example here and even more at the blog main menu item of this demo.
https://www.sifact.it/wp-content/uploads/2026/09/8.10.26-cop.jpg
714
844
Segreteria SIFaCT
https://www.sifact.it/wp-content/uploads/2019/12/logo_sifact_0-300x111.png
Segreteria SIFaCT2026-09-07 15:46:102026-09-07 15:46:12IL FUTURO DELL’ EMATO-ONCOLOGIA GOVERNARE L’INNOVAZIONE – Bologna, 08/10/2026
https://www.sifact.it/wp-content/uploads/2026/09/medreview-cop.jpg
282
757
Segreteria SIFaCT
https://www.sifact.it/wp-content/uploads/2019/12/logo_sifact_0-300x111.png
Segreteria SIFaCT2026-08-31 14:50:532026-09-07 14:55:42Corso di Perfezionamento in Medication Review e Deprescribing – A.A. 2026/2027
https://www.sifact.it/wp-content/uploads/2026/09/carenet26cop.jpg
944
1356
Segreteria SIFaCT
https://www.sifact.it/wp-content/uploads/2019/12/logo_sifact_0-300x111.png
Segreteria SIFaCT2026-08-31 14:27:522026-09-07 14:48:25CARE NETWORK Il farmacista clinico – Dr.ssa Marra – Ferrara, 24-25 settembre 2026
https://www.sifact.it/wp-content/uploads/2019/12/logo_sifact_0.png
481
1298
Segreteria SIFaCT
https://www.sifact.it/wp-content/uploads/2019/12/logo_sifact_0-300x111.png
Segreteria SIFaCT2026-08-06 11:52:592026-08-06 16:51:10Bando per l’acquisizione delle candidature finalizzate alla formazione del nuovo Comitato Scientifico
https://www.sifact.it/wp-content/uploads/2019/12/logo_sifact_0-300x111.png
0
0
Segreteria SIFaCT
https://www.sifact.it/wp-content/uploads/2019/12/logo_sifact_0-300x111.png
Segreteria SIFaCT2026-07-16 15:04:502026-07-16 15:04:51Long-term outcomes of ALK inhibitors in metastatic ALK-positive non-small cell lung cancer: an updated indirect comparison using reconstructed patient-level data
https://www.sifact.it/wp-content/uploads/2019/12/logo_sifact_0-300x111.png
0
0
Segreteria SIFaCT
https://www.sifact.it/wp-content/uploads/2019/12/logo_sifact_0-300x111.png
Segreteria SIFaCT2026-07-16 15:01:182026-07-16 15:01:19Efficacy and safety of first-line osimertinib monotherapy versus osimertinib plus platinum-based chemotherapy or amivantamab plus lazertinib in metastatic EGFR-mutated NSCLC: an indirect comparison
PharmAgorà Veneto: Esperienze, Incontri, Confronti di Farmacia Clinica – Padova, 18/09/2026